Ardelyx, Inc.

Ardelyx, Inc. is a commercial-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative, first-in-class medicines designed to address significant unmet medical needs. The company's mission is centered on improving the lives of patients, particularly those affected by cardiorenal and gastrointestinal conditions. Headquartered in Waltham, Massachusetts, Ardelyx leverages a proprietary drug discovery platform to create targeted therapies.

Ardelyx's primary commercial products in the United States are IBSRELA® (tenapanor), approved for the treatment of Irritable Bowel Syndrome with Constipation (IBS-C), and XPHOZAH® (tenapanor), indicated to reduce serum phosphorus in adults with Chronic Kidney Disease (CKD) on dialysis. The company focuses its market efforts on these specific gastrointestinal and cardiorenal disease segments. Its pipeline includes the Phase 3 development of IBSRELA for chronic idiopathic constipation (CIC) and RDX10531, a next-generation NHE3 inhibitor with potential for broader therapeutic applications.

In recent news, Ardelyx reported strong commercial execution in Q1 2026, with total product revenue growing 38% year-over-year, significantly driven by IBSRELA sales. The company continues to expand its executive leadership team, with recent appointments including Rajani Dinavahi, M.D. as Chief Medical Officer and Felecia W. Ettenberg, Esq. as Chief Legal Officer in April 2026. Ardelyx is strategically positioned to capture market share in its therapeutic areas, aiming for at least $1 billion in annual revenue by 2029 through continued product growth and pipeline advancement.